Scholar Rock Holding Corp (SRRK) FY2025 10-K Annual Report
Scholar Rock Holding Corp (SRRK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Scholar Rock Holding Corp FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
- • New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
- • Strategic shift: Transitioning to global commercial-stage biotech; appointed new CEO and expanded U.S./European commercial teams (~50 employees)
- • Notable metric: Submitted BLA for apitegromab in SMA in Jan 2025; received FDA Priority Review and EMA MAA acceptance in March 2025
- • Unique fact: Apitegromab is first myostatin inhibitor with positive Phase 3 SAPPHIRE study outcome and plans to target additional indications including infants under 2 years and FSHD
Management Discussion & Analysis
- • Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
- • R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
- • Apitegromab R&D costs rose 14.7% to $89.8M; SRK-181 decreased 75.8%, SRK-439 decreased 22.9%
- • Cash, cash equivalents, and securities $367.6M at 2025 YE, down $69.7M YoY; net cash used in operations $300.0M
- • Raised $91.7M from ATM stock sales, $50M from debt facility, $63.8M from warrant exercises in 2025
- • FDA CRL for apitegromab due to third-party fill-finish issues; resubmission pending resolution, Phase 2 trial in FSHD planned mid-2026
- • Management expects ongoing substantial expenses for R&D, commercialization, and infrastructure build ahead of potential apitegromab launch
Risk Factors
- • FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
- • Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
- • Supply chain risk: reliance on limited third-party manufacturers for materials, with potential interruptions or quality issues impacting clinical/commercial supplies
- • Competitive risk: dependence on continued availability of approved SMN-targeted treatments (e.g., nusinersen, risdiplam) for apitegromab trials; limited access could halt trials
- • Financial risk: ongoing net losses and urgent need for additional capital to fund development and commercialization of apitegromab, SRK-181, SRK-439
Scholar Rock Holding Corp FY2025 Key Financial MetricsXBRL
Revenue
$0
Net Income
-$378M
▼ -53.5% YoY
ROE
-154.0%
▼ -8714bp YoY
Total Assets
$404M
▼ -14.9% YoY
EPS (Diluted)
$-3.29
▼ -33.2% YoY
Operating Cash Flow
-$300M
▼ -49.3% YoY
Source: XBRL data from Scholar Rock Holding Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Scholar Rock Holding Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.